[go: up one dir, main page]

DE60029929D1 - VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN - Google Patents

VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN

Info

Publication number
DE60029929D1
DE60029929D1 DE60029929T DE60029929T DE60029929D1 DE 60029929 D1 DE60029929 D1 DE 60029929D1 DE 60029929 T DE60029929 T DE 60029929T DE 60029929 T DE60029929 T DE 60029929T DE 60029929 D1 DE60029929 D1 DE 60029929D1
Authority
DE
Germany
Prior art keywords
pyridazino
indole
medicament
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60029929T
Other languages
English (en)
Other versions
DE60029929T2 (de
Inventor
Badia Ferzaz
Jesus Benavides
Frank Marguet
Jacques Froissant
Benoit Marabout
Yannick Evanno
Mireille Sevrin
Philip Janiak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE60029929D1 publication Critical patent/DE60029929D1/de
Application granted granted Critical
Publication of DE60029929T2 publication Critical patent/DE60029929T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60029929T 1999-01-26 2000-01-21 VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN Expired - Lifetime DE60029929T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9900806 1999-01-26
FR9900806A FR2788696B1 (fr) 1999-01-26 1999-01-26 Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
PCT/FR2000/000135 WO2000044384A1 (fr) 1999-01-26 2000-01-21 UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES

Publications (2)

Publication Number Publication Date
DE60029929D1 true DE60029929D1 (de) 2006-09-21
DE60029929T2 DE60029929T2 (de) 2007-08-30

Family

ID=9541212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60029929T Expired - Lifetime DE60029929T2 (de) 1999-01-26 2000-01-21 VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN

Country Status (32)

Country Link
US (1) US6395729B1 (de)
EP (1) EP1148881B1 (de)
JP (1) JP4688295B2 (de)
KR (1) KR100694752B1 (de)
CN (1) CN100577167C (de)
AR (1) AR022413A1 (de)
AT (1) ATE335487T1 (de)
AU (1) AU764445B2 (de)
BG (1) BG65152B1 (de)
BR (1) BR0007718A (de)
CA (1) CA2360754C (de)
CO (1) CO5160242A1 (de)
CY (1) CY1106257T1 (de)
CZ (1) CZ294283B6 (de)
DE (1) DE60029929T2 (de)
DK (1) DK1148881T3 (de)
EE (1) EE04905B1 (de)
ES (1) ES2269097T3 (de)
FR (1) FR2788696B1 (de)
HK (1) HK1040905B (de)
HU (1) HU228670B1 (de)
IL (2) IL144181A0 (de)
NO (1) NO321997B1 (de)
NZ (1) NZ512981A (de)
PL (1) PL193420B1 (de)
PT (1) PT1148881E (de)
RU (1) RU2243764C2 (de)
SK (1) SK285707B6 (de)
TR (1) TR200102134T2 (de)
TW (1) TW541177B (de)
UA (1) UA70349C2 (de)
WO (1) WO2000044384A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100302A (et) * 1998-12-02 2002-08-15 Pfizer Products Inc. Meetodid ja kompositsioonid p53 perekonna valgu konformatsioonilise stabiilsuse taastamiseks
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2838124B1 (fr) * 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR2876715B1 (fr) 2004-10-19 2006-12-15 Profiles Du Ct Sa Embout de protection pour ecran de glissiere de securite routiere
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
WO2007086911A2 (en) * 2005-05-05 2007-08-02 Sanofi-Aventis U.S. Llc Stable nanoparticle formulations
ES2375841T3 (es) * 2005-08-29 2012-03-06 Sanofi-Aventis U.S. Llc Nueva forma cristalina de un derivado de piridazino[4,5-b]indol.
SI1926476T1 (sl) * 2005-08-29 2013-07-31 Sanofi-Aventis U.S. Llc Amorfne trdne disperzije 7-kloro-N,N,5-trimetil-4-okso-3-fenil-3,5- dihidro-4H-piridazino/4,5-b/indol-1-acetamida
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane
CN102186854A (zh) * 2008-08-18 2011-09-14 赛诺菲-安万特美国有限责任公司 制备7-氯-N，N，5-三甲基-4-氧代-3-苯基-3，5-二氢-4H-哒嗪并[4，5-b]吲哚-1-乙酰胺的多晶型的方法
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
EP2181717A1 (de) * 2008-10-28 2010-05-05 Sanofi-Aventis Verwendung von 7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indol-1-Acetamid als Biomarker für periphere Benzodiazepin-Rezeptorverteilung
EP2512416A2 (de) 2009-12-18 2012-10-24 L'Oréal Kosmetisches behandlungsverfahren mit einer in-situ kondensierbaren verbindung
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) * 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
US6031120A (en) * 1997-07-29 2000-02-29 E. I. Du Pont De Nemours And Company Selective synthesis of organodiphosphite compounds
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NO20013645L (no) 2001-09-26
UA70349C2 (en) 2004-10-15
NO20013645D0 (no) 2001-07-24
EE04905B1 (et) 2007-10-15
EE200100388A (et) 2002-12-16
BG65152B1 (bg) 2007-04-30
HUP0201280A3 (en) 2004-12-28
DK1148881T3 (da) 2006-12-11
NO321997B1 (no) 2006-07-31
HU228670B1 (en) 2013-05-28
IL144181A0 (en) 2002-05-23
PL349364A1 (en) 2002-07-15
JP4688295B2 (ja) 2011-05-25
AR022413A1 (es) 2002-09-04
WO2000044384A1 (fr) 2000-08-03
RU2243764C2 (ru) 2005-01-10
CN1344161A (zh) 2002-04-10
PL193420B1 (pl) 2007-02-28
ES2269097T3 (es) 2007-04-01
CY1106257T1 (el) 2011-06-08
TW541177B (en) 2003-07-11
CO5160242A1 (es) 2002-05-30
CN100577167C (zh) 2010-01-06
FR2788696A1 (fr) 2000-07-28
IL144181A (en) 2007-06-17
EP1148881A1 (de) 2001-10-31
JP2002535370A (ja) 2002-10-22
SK10502001A3 (sk) 2002-01-07
SK285707B6 (sk) 2007-06-07
ATE335487T1 (de) 2006-09-15
CA2360754A1 (en) 2000-08-03
EP1148881B1 (de) 2006-08-09
CZ20012681A3 (cs) 2001-10-17
HUP0201280A2 (en) 2002-08-28
NZ512981A (en) 2002-10-25
HK1040905A1 (en) 2002-06-28
KR20010089624A (ko) 2001-10-06
FR2788696B1 (fr) 2004-03-05
DE60029929T2 (de) 2007-08-30
CZ294283B6 (cs) 2004-11-10
KR100694752B1 (ko) 2007-03-14
TR200102134T2 (tr) 2003-03-21
CA2360754C (en) 2008-07-08
BG105728A (en) 2002-02-28
US6395729B1 (en) 2002-05-28
BR0007718A (pt) 2001-11-13
HK1040905B (zh) 2007-02-23
AU764445B2 (en) 2003-08-21
AU3057900A (en) 2000-08-18
PT1148881E (pt) 2006-12-29

Similar Documents

Publication Publication Date Title
DE60029929D1 (de) VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ATE262331T1 (de) Heterocyclische vinylether zur behandlung neurologischer krankheiten
ATE86491T1 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE59608861D1 (de) Verwendung von N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl]-2,2-diphenyl-acetamid Hydrochlorid zur Herstellung von Arzneimitteln zur Behandlung von entzündlichen Darmerkrankungen
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE338575T1 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
ATE253905T1 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition